-
2021 CSCO Professor Xu Wei: Research Progress of Chronic Lymphocytic Leukemia
Time of Update: 2021-10-22
The Phase II CAPTIVATE study explored the efficacy of a fixed course of Ibrutinib combined with the Bcl-2 inhibitor Venecla regimen in the treatment of CLL .
The Phase III GLOW study also explored the efficacy of a fixed course of Ibrutinib combined with Venecla in the first-line treatment of CLL .
-
Professor Liu Qifa: The guideline treatment pattern is changing with each passing day, and the AML treatment concept is constantly improving
Time of Update: 2021-10-22
Of particular importance is that the new version of the guidelines has increased the usage, dosage and combination of BCL-2 inhibitor venecola, increased targeted drugs geritinib and sorafenib for the treatment of patients with FLT3 mutations, and increased IDH1 Inhibitors, IDH2 inhibitors and other related content .
-
2021 CSCO Expert Interview｜Professor Cai Qingqing talks about the treatment progress of diffuse large B-cell lymphoma
Time of Update: 2021-10-22
In addition, last year’s ASCO and ESMO meeting reported the results of a phase I/II study of CD19/CD22 dual-targeting CAR-T cells (AUTO3) combined with PD-1 monoclonal antibody for the treatment of R/R DLBCL, using different doses of AUTO3 alone or in combination The ORR of pembrolizumab-treated patients was 68%, the CR rate was 54%, and the duration of complete remission was long.
-
CCSC: Looking around the world, knowing the international vision of CAR-T in the treatment of lymphoma
Time of Update: 2021-10-22
This conference is fortunate to invite Professor Song Yuqin from Peking University Cancer Hospital, Professor Sattva Neelapu from MD Anderson Cancer Center and many top domestic experts as speakers and discussion guests, focusing on cutting-edge topics in the field of CAR-T cell therapy.
-
Professor Zhang Huilai talks about the treatment of follicular lymphoma: Otuzumab significantly reduces the risk of POD24 and brings better prognosis
Time of Update: 2021-10-22
The humanized glycosylated type II anti-CD20 monoclonal antibody-Otuzumab was approved in China in June this year and used in combination with chemotherapy for the first-line induction therapy of newly-treated adult patients with follicular lymphoma (FL) After achieving at least partial remission, the monotherapy of Otuzumab maintenance therapy will bring new hope for meeting the treatment needs of Chinese FL patients .
-
2021 CSCO Professor Junning Cao: Progress in the treatment of Hodgkin’s lymphoma
Time of Update: 2021-10-22
The results of the HD9 study on the treatment of stage III/IV HL for newly-treated patients showed that compared with ABVD regimen, BEACOPP regimen can bring better curative effect for patients with stage III/IV HL .
-
2021 CSCO Professor Chen Wenming: Progress in the treatment of relapsed and refractory multiple myeloma
Time of Update: 2021-10-22
Professor Chen Wenming said that for RRMM patients who relapse after maintenance treatment with lenalidomide and are not resistant to bortezomib, the PVd regimen is also a better treatment option .
-
Science Advances Shanghai Jiaotong University Zhujiang/Shi Jun discovered a potential therapeutic target for acute myeloid leukemia
Time of Update: 2021-10-22
In terms of mechanism, IL-36 directly activates inflammatory monocytes (IM) in the bone marrow, and then prevents the elimination of leukemia mediated by CD8+ T cells and promotes the growth of LP .
-
2021 CSCO Professor Zhou Guoren: The harm of tumor-related anemia and its full management
Time of Update: 2021-10-22
The results of a double-blind placebo-controlled study of gastrointestinal cancer patients showed that the intraoperative blood transfusion rate of patients in the EPO treatment group and the placebo group was 29.
-
Risk prediction and immune infiltration profile of patients with diffuse large B-cell lymphoma based on gene expression profile
Time of Update: 2021-10-22
Prof. Hui Zhou, Director of the Department of Lymphoma and Hematology, Hunan Cancer Hospital, Dr. Selin Merdan, Department of Industrial and Systems Engineering, Georgia Institute of Technology, US
-
2021 CSCO Expert Interview｜Professor Deng Qi talks about the treatment progress of extramedullary multiple myeloma
Time of Update: 2021-10-22
At this conference, Professor Deng Qi from the Department of Hematology, Tianjin First Central Hospital stated that -The efficacy of T cell therapy in patients with relapsed/refractory multiple myeloma with and without extramedullary lesions" was reported on the topic .
-
STTT Nanjing University of Traditional Chinese Medicine Yang Ye/Gu Xiaosong/Gu Chunyan found a new potential therapeutic target for multiple myeloma
Time of Update: 2021-10-22
iNature multiple myeloma (MM) is an incurable plasma cell malignant tumor in the bone marrow, which is characterized by chromosomal instability (CIN), which can lead to the acquisition of heterogeneity, and the progression of multiple myeloma, Resistance and relapse .
-
Professor Jin Jie: From initial treatment to R/R, the new guidelines establish new standards for AML diagnosis and treatment
Time of Update: 2021-10-22
However, in recent years, with the vigorous development of targeted drugs such as the BCL-2 inhibitor Veneclax, and the continuous enrichment of evidence-based evidence, it has brought great changes to the diagnosis and treatment of AML, and promoted the diagnosis and treatment guidelines and relapse/recurrence of AML in Chinese adults in 2021.
-
2021 CSCO Expert Interview｜Professor Zhu Jun: lonca shows preliminary efficacy, the prospects of R/R DLBCL new drug application are worth looking forward to
Time of Update: 2021-10-22
At the CSCO conference, Professor Zhu Jun from Peking University Cancer Hospital introduced an ongoing antibody-drug conjugate loncastuximab tesirine (lonca) for the treatment of Chinese patients with relapsed and refractory diffuse large B-cell lymphoma (R/R DLBCL) II Period research .
-
2021 CSCO Expert Interview｜Professor Zhang Yizhuo: New progress in the treatment of lymphoma in children and adolescents
Time of Update: 2021-10-22
In 2020, the results of an international multi-center, randomized, phase III clinical trial led by the European Pediatric Lymphoma International Collaboration Group (EICNHL) and the United States Children’s Oncology Collaboration Group (COG) showed that the combination on the basis of standard LMB chemotherapy regimens Rituximab can significantly prolong the event-free survival (EFS) and OS of children and adolescents with high-risk mature B-cell lymphoma, and the 5-year OS rate has increased to 95%.
-
2021 CSCO Professor Gong Tiejun: Progress in the treatment of acute lymphoblastic leukemia
Time of Update: 2021-10-22
The 5-year long-term follow-up results of the study showed that belintoomab can provide long-term survival benefits for MRD-positive ALL patients, with a median OS of 36.
-
2021 CSCO Professor Liang Aibin: The whole course management of CAR-T treatment
Time of Update: 2021-10-22
Professor Liang Aibin then introduced the CAR-T treatment process, including disease diagnosis, patient enrollment, informed consent, data collection, cell collection, CAR-T production, hospital admission, clinical risk control, patient follow-up and so on .
-
Professor Li Jianyong: Diagnosis and Treatment of Chronic Lymphocytic Leukemia The 16th National Leukemia and Lymphoma Academic Conference
Time of Update: 2021-10-22
The results of a study exploring the treatment of relapsed and refractory CLL/SLL with a new BTK inhibitor Zebutinib showed that at a median follow-up of 34 months, the CR rate of Zebutinib in the treatment of relapsed and refractory CLL/SLL reached 13.
-
The multi-center collaboration group for systemic mastocytosis was officially launched, bringing more benefits to patients
Time of Update: 2021-10-22
On the afternoon of October 9th, the multi-center research sub-venue of the Suzhou Hematology Summit successfully held the launching ceremony of the China Systemic Mastocytosis (SM) Multi-center Collaborative Group and the first SM academic conference.
-
2021 CSCO Professor Li Zhiming: Progress in the treatment of Hodgkin’s lymphoma
Time of Update: 2021-10-22
This year’s EHA conference announced the 5-year follow-up results of the ECHELON-1 study exploring the combination of verbutuximab (BV) and chemotherapy in the treatment of newly treated stage III/IV cHL .
